Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Accumulated Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Accumulated Expenses for 9 consecutive years, with $403000.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed N/A to $403000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $403000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $403000.0 for FY2025, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2025 was $403000.0 at Soleno Therapeutics, down from $7.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $7.2 million in Q3 2025, with the low at $403000.0 in Q4 2025.